AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00000421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01697735
Drug: Atorvastatin or Rosuvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
Trial: NCT05238402
Drug: Statin
RxNorm normalized name: Statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin on COVID 19 patienst
Trial: NCT00777608
Drug: Comparator: Placebo 5mg (run in)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
Trial: NCT00777608
Drug: Comparator: Placebo 5-10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.~Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84).
Trial: NCT01383486
Drug: Naproxen sodium ER (BAYH6689)
RxNorm normalized name: naproxen Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
Trial: NCT00655590
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebos
Trial: NCT01370369
Drug: Testosterone gel (FE 99903)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02297763
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo is made of 100mg of corn starch which is melted in 10cc water.
Trial: NCT01986491
Drug: JNJ 39393406 30 mg solid Y
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Trial: NCT01605526
Drug: RO5045337
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
Trial: NCT01605526
Drug: doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
Trial: NCT01986491
Drug: JNJ 39393406 120 mg solid Y
RxNorm normalized name: Y
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
Trial: NCT00123734
Drug: ThromboView
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01471886
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Every 8 hours for 4 days.
Trial: NCT00960336
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02580279
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01188889
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing schedule of RAD001 for the Phase I portion:~Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD.
Trial: NCT02574377
Drug: A: myDC vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02574377
Drug: C: combined myDC/pDC vaccination
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03620591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative administration of normal saline
Trial: NCT02257658
Drug: Doxycycyline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01202331
Drug: mass treatment with oral azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
Trial: NCT01531920
Drug: placebo + alcohol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part B: placebo + alcohol
Trial: NCT03574090
Drug: Physiological Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To demonstrate its efficacy in the prophylaxis of infection to surgical wound will be used in dirty/contaminated emergency surgery and its efficacy will be compared with topical administration of physiological serum alone.
Trial: NCT03451773
Drug: M7824
RxNorm normalized name: M7824
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,200 or 500mg every 2 weeks by intravenous (IV) infusion
Trial: NCT02603120
Drug: ABC/DTG/3TC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600/50/300 mg FDC tablets administered orally once daily without regard to food
Trial: NCT02603120
Drug: B/F/TAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50/200/25 mg FDC tablets administered orally once daily without regard to food
Trial: NCT02603120
Drug: ABC/DTG/3TC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily without regard to food
Trial: NCT02603120
Drug: B/F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets administered orally once daily without regard to food
Trial: NCT02469753
Drug: anti-TNF
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01566773
Drug: PT001 Placebo MDI
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00670319
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo one tab orally per day
Trial: NCT02294786
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine (Xeloda™) was supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contained 150mg Capecitabine and each peach colored tablet contained 500mg Capecitabine. Generic versions of capecitabine may have been used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
Trial: NCT00647686
Drug: Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00647686
Drug: Fentanyl Transdermal System 25 mcg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single application
Trial: NCT00784420
Drug: UK-453,061
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UK-453,061 1000 mg once daily for 10 days
Trial: NCT01500109
Drug: Oral acetaminophen
RxNorm normalized name: acetaminophen Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Trial: NCT01500109
Drug: Ofirmev®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Trial: NCT01500109
Drug: Opioid only
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
Trial: NCT00244764
Drug: GW786034
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Trial: NCT00244764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
Trial: NCT02614586
Drug: TAK-058 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAK-058 placebo-matching, solution.
Trial: NCT01849874
Drug: MEK162, MEK inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, single schedule
Trial: NCT01849874
Drug: Physician's choice chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive one of the following chemotherapies as determined by the physician:~* Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)~* Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)~* Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)
Trial: NCT03080298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01445561
Drug: Interleukin-2 (100,00 IU/m(2) SQ)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100,000 International Units/m2 SQ daily for 5 days
Trial: NCT00003437
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003437
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003437
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003437
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03951623
Drug: HMPL-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Trial: NCT03951623
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMPL-523 matching placebo will be oral administrated once daily for 8 weeks and 16 weeks open-label treatment.
Trial: NCT01631383
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
Trial: NCT00923390
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00977951
Drug: Placebo (vehicle)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
Trial: NCT01007773
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl will be initiated and titrated to achieve adequate pain control.
Trial: NCT00977951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
Trial: NCT00299104
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral or parenteral repeating dose
Trial: NCT00299104
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous repeating dose
Trial: NCT03375775
Drug: Subcutaneous immunotherapy with ALK Alutard birch or ALK Alutard timothy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to standardized clinical protocol
Trial: NCT00657891
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Injection
Trial: NCT01305538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00385645
Drug: Combivir+Reyataz
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00978029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo sublingual tablet, once daily
Trial: NCT03615196
Drug: USB005 Ophthalmic Solution Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A clinical placebo formulated with the same excipients and packaged in the same container closure system as the active product, USB005 (aclerastide) Ophthalmic Solution.
Trial: NCT04422860
Drug: Proflourid Varnish,VOCO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% NaF varnish
Trial: NCT04422860
Drug: MI Varnish,GC Japan Inc.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP-ACP with fluoride based varnish
Trial: NCT00899054
Drug: P276-00
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
Trial: NCT00767091
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: transdermal patch of placebo
Trial: NCT03016325
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion
Trial: NCT00731575
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
Trial: NCT03424707
Drug: DW340(pelubiprofen/eperisone)
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DW340
Trial: NCT03424707
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Oral Tablet
Trial: NCT00131391
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule once daily . 52 week treatment period.
Trial: NCT01352091
Drug: Zoladex+AI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
Trial: NCT03969121
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and peri-menopausal women will be receiving Ovarian Function Suppression (OFS) by either leuprorelin subcutaneous 3.75 mg q28days or goserelin subcutaneous 3.6 mg q28days plus tamoxifen 20 mg QD in 28-day cycles. Post-menopausal women will receive letrozole 2.5 mg QD in 28-day cycles.
Trial: NCT00812058
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
Trial: NCT00083031
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00083031
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00886600
Drug: Comparator: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
Trial: NCT01708642
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative isotonic saline infusion as placebo for adrenaline.
Trial: NCT01696240
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
Trial: NCT00586209
Drug: L-Glutamine
RxNorm normalized name: L-Glutamine
DrugBank: L-Glutamine (DB00130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (\>66.7 kg)
Trial: NCT00586209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
Trial: NCT02343172
Drug: HDM201
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02343172
Drug: LEE011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01179009
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV saline (i.e. placebo ketamine)
Trial: NCT04229225
Drug: UBX0101
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational drug intra-articular (IA) injection
Trial: NCT00503477
Drug: AZD2171
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet
Trial: NCT04460547
Drug: Convalescent Plasma Transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent Plasma Transfusion to COVID-19 infected patients.
Trial: NCT00092846
Drug: MK0803, lovastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02398591
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
Trial: NCT04460547
Drug: DAS181
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAS181 administration to COVID-19 infected patients.
Trial: NCT03358888
Drug: Multi-modal with as needed opioids
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal with as needed oxycodone and tramadol provided for break-through pain
Trial: NCT03358888
Drug: Multi-modal with one week of opioids offered
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-modal with only one week of oxycodone and tramadol provided for emergency pain relief only
Trial: NCT03358888
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm follows standard of care post-operative pain management with oxycodone, tramadol, and acetametophin
Trial: NCT03972683
Drug: Acetylcholine
RxNorm normalized name: Acetylcholine
DrugBank: Acetylcholine (DB03128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vasodilatory sensitivity to acetylcholine will be assessed in dose-response fashion as a standard test of vascular function. Doses of 0.5, 1.5, and 15 μg/dl forearm volume/min will be infused via a brachial artery catheter for 4 min per dose.
Trial: NCT01748539
Drug: KHK4827
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01748539
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03563378
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administered normal saline for intraoperative fluid management.
Trial: NCT01075555
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02940509
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
Trial: NCT00859105
Drug: Adara 5% Cream US
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
Trial: NCT00859105
Drug: Adara 5% Cream Canada
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
Trial: NCT01660945
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01175135
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet/capsule every 12 hours for 28 days
Trial: NCT00222625
Drug: FFP or aPCC+ vit K in AO treated patients
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01061814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks